BDBM575603 (2S,2'S,4R,4'R)-1,1'-(((((2,2'- dimethyl-[1,1'-biphenyl]-3,3'- diyl)bis(azanediyl))bis(carbonyl))bis (4-methoxypyridine-6,3-diyl))bis (methylene))bis(4-hydroxypyrrolidine- 2-carboxylic acid)::US11459339, Example 62

SMILES COc1cc(ncc1CN1C[C@H](O)C[C@H]1C(O)=O)C(=O)Nc1cccc(c1C)-c1cccc(NC(=O)c2cc(OC)c(CN3C[C@H](O)C[C@H]3C(O)=O)cn2)c1C

InChI Key InChIKey=AKULDDQUEASVMI-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 575603   

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575603(US11459339, Example 62 | (2S,2'S,4R,4'R)-1,1'-((((...)
Affinity DataIC50: 0.25nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent